Clinical Trials
14 trialsNCT06904066 2026-06-04
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04013685 2026-06-02
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Phase 1 Active not recruiting
NCT07527221 2026-06-01
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Phase 1 Recruiting
NCT02091245 2026-05-29
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT03326921 2026-05-18
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT05088356 2026-05-12
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
Phase 1 Active not recruiting
NCT00720785 2026-05-07
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07302776 2026-04-17
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Phase 1 Not yet recruiting
NCT07166419 2026-04-15
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT07254793 2026-04-07
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
Phase 1 Not yet recruiting
NCT05304377 2026-04-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT03533816 2026-03-25
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
University of Kansas Medical Center
Phase 1 Recruiting
NCT06994676 2026-03-16
CROSSCHECK-001
Crossbow Therapeutics, Inc.
Phase 1 Recruiting